Introduction ( J.M. Miro, A. Rimola)
Since the introduction of combined anti-retroviral therapy (ART) in the mid-1990s and the subsequent drastic reduction in mortality by HIV infection [1] , liver diseases, particularly those related to hepatitis C virus (HCV) infection, have become a leading cause of death in HIV-infected individuals [2] . Consequently, liver transplantation (LT) has been increasingly necessary in this population and has been performed in selected HIV-infected patients in many developed countries [3, 4] , mainly the United States of America (USA), France and Spain. Excellent results have been reported for LT in HIV-infected patients with liver diseases unrelated to HCV [5, 6] . In contrast, survival in HCV/HIV-coinfected patients has been poorer than in HCV-monoinfected patients [7] [8] [9] [10] . The main reason for this difference is that recurrent HCV is more aggressive in coinfected recipients and is the major cause of graft loss and death in this group [7] [8] [9] [10] . Therefore, it is still debated whether LT should be offered to HCV/HIV-coinfected patients.
The objective of this non-systematic review of the literature is to bring together experience on LT in HCV/HIV-coinfected liver recipients gained by American [10] , French [8] , and Spanish [9] investigators during the last decade. We discuss what we have learnt about different aspects of this issue, provide recommendations and present future challenges considering the introduction of new anti-HCV direct antiviral agents (DAAs). Recommendations are rated based on the Infectious Diseases Society of America -United States Public Health Service evidence grading system (Table 1 ) [11] .
• The rates of sustained virological response with pegylated-interferon plus ribavirin in HCV/HIV coinfected recipients are low, particularly for genotype 1 (only 10%). However, the 5-year survival is almost 80% in co-infected patients whose HCV infection was cleared • The recent introduction of the new potent and more tolerable direct-acting antiviral agents (DAAs) offers hope for significant improvements in the outcome of HCV/HIV co-infected liver transplant recipients • This review covers selection criteria in HIVinfected patients, pre-and post-liver transplantation management, donor selection, anti-HCV treatment, drug interactions with antiretrovirals and anti-HCV DAAs, hepatocellular carcinoma, and liver retransplantation
Pre-transplant issues ( J.M. Miro, A. Rimola)
Patient referral for LT
The risk of death after the first episode of clinical liver decompensation is higher in HIV/HCV-coinfected than in HCV-monoinfected patients with cirrhosis, with a median survival time of 16 and 48 months, respectively [12] . Thus, it seems judicious to refer these patients for LT early after the first episode of clinical decompensation.
Criteria for LT indication
The criteria for LT in HIV-infected patients are the same as for non-HIV-infected persons in all centers. Additionally, HIVinfected patients must have a favorable psychosocial evaluation and have abstained from drug and/or alcohol consumption [13] . Initially, the HIV-related criteria for LT were the absence of previous AIDS-defining events (ADE), CD4+ T-cell count >200 cells/mm 3 , and full suppression of HIV replication by ART [13] . However, these criteria have been modified over time.
Although LT candidates should ideally not have a history of ADE, most groups currently include patients with previous opportunistic infections that can be treated and prevented effectively, such as tuberculosis, esophageal candidiasis, and Pneumocystis jiroveci pneumonia. In fact, the US multicenter cohort study recently expanded the criteria for LT, and only untreatable diseases continue to be exclusion criteria for LT (e.g., progressive multifocal leukoencephalopathy, chronic cryptosporidiosis, multidrug-resistant systemic fungal infections and primary CNS lymphoma). In light of the efficacy of the immunosuppressive agent sirolimus in the treatment of Kaposi's sarcoma, potential recipients with resolved systemic Kaposi's sarcoma may be considered for transplantation provided that they meet the other criteria [3] .
At present, a minimum CD4+ T-cell count of 100 cells/mm 3 is required in almost all centers [3, 8, [13] [14] [15] , although in most countries this limit is increased to 200 cells/mm 3 in specific circumstances, such as previous history of opportunistic infections (USA and Spain), clinically compensated cirrhosis (Italy), and absence of portal hypertension (UK). HIV should be suppressed in all patients on ART [3, 8, [13] [14] [15] . In patients with transiently detectable viral load, effective, safe, and long-lasting ART must be ensured after LT.
The current HIV-related criteria for LT are summarized in Table 2 . Nevertheless, it should be noted that these criteria were established on the basis of common sense, but have not been validated with appropriate studies yet.
Waiting list management
The risk of death in HIV-infected patients on the waiting list increases sharply with the MELD score (MELD <15), as follows: HR = 5.7 for MELD 15-19, HR = 21.4 for MELD 20-24, and HR = 101 for MELD P25. After adjustment for baseline CD4 count and detectability of HIV RNA, the risk of waiting list mortality increased by 20% for each unit increase in MELD from baseline [16] . Once a patient is included on the waiting list, MELD has been shown to accurately reflect the short-term risk of mortality and priority for LT [16] . Therefore, there are no MELD exceptions ART, (b) a CD4+ T-cell count >100/ll, and (c) no previous ADEs, although some preventable opportunistic infections can be included (AIII).
Challenges
1. To define the specific timing for referring patients to a liver transplant unit. 2. To validate current HIV-specific criteria for LT with the aim of determining which of these criteria -if any -need to be modified to improve long-term post-transplant outcomes.
The poorer results observed in coinfected liver transplant recipients than in HCV-monoinfected patients may be related to the quality of the donor organs [9, 10] . The donor risk index, which estimates the relative risk of graft failure based on donor characteristics, is associated with graft loss in both coinfected and monoinfected groups in the USA and Spanish multicenter cohort studies [9, 10] . However, within the HCV/HIV-coinfected cohort, the use of anti-HCV-positive and older donors were both independent predictors of poor outcome in a multivariate analysis [10] . Poorer outcomes with older donors have also been observed in HCV-monoinfected recipients, prompting many centers to exclude donors over the age of 50 in the case of HCV-infected recipients. The use of HCV-infected donors in HCV-monoinfected recipients had no impact on graft or patient survival compared with HCV-negative donors, provided that the donor biopsy revealed no evidence of fibrosis. However, the practice of using HCV-infected donors in genotype 1 HCV/HIV-coinfected patients resulted in significantly poorer outcome in the coinfected recipients [10] . The American cohort study [5] does not recommend the use of older donors (>50 years) or HCV-infected donors (even when histology results are normal). Of note, these restrictions on donors will likely be less relevant with the increasingly frequent use of DAAs. Several cohort studies, systematic reviews, and meta-analyses have demonstrated that patient and graft survival rates are poorer in HCV/HIV-coinfected transplant recipients than in HCV-monoinfected recipients [17] [18] [19] . Table 3 shows the survival rate reported in 3 published national HCV/HIV-coinfected liver transplant cohort studies, and compares outcomes with their respective HCV-monoinfected counterparts [8] [9] [10] . In the French and Spanish studies, 5-year survival in HCV/HIV-coinfected patients vs. HCV-monoinfected patients was 51% vs. 81%, and 54% vs. 71%, respectively. In the American study, 3-year survival was 60% vs. 79%. As shown in Table 4 , HIV coinfection was identified as an independent predictor for mortality in the American and Spanish studies. Importantly, recurrence of HCV was the most frequent cause of death in coinfected patients from the French and Spanish cohorts and the second cause of death in coinfected patients from the American study [8] [9] [10] . Table 4 summarizes the variables identified as prognostic factors in HCV/HIV-coinfected LT recipients in the American and Spanish cohort studies [9, 10] , as well as in the whole series of HCV/HIV-coinfected and HCV-monoinfected patients taken together in the French study [8] . Donor age or donor risk index (of which donor age is a major component) were predictive of mortality in the three series. Other factors adversely influencing survival in the American study were a low pre-transplant body mass index (BMI <21 kg/m 2 ), combined liver-kidney transplantation, and, the use of HCV-infected grafts (see above). Since in the other two studies no combined liver-kidney transplantation was performed and no HCV-infected donors were used, the prognostic value of these variables could not be assessed in the French and Spanish cohorts. BMI did not have prognostic significance in the Spanish study, although very few patients had a BMI lower than 21 kg/m 2 ; therefore, this threshold could not be properly assessed. BMI was not investigated in the French cohort. Only in the Spanish study, HCV genotype 1 was associated with increased mortality; however, because of the availability of new antiviral therapies, soon this genotype may no longer be considered a poor prognostic factor. Negative serum HCV RNA remarkably improved the probability of survival in the Spanish cohort; no information on this variable was given in the other studies. Interestingly, in the French and the Spanish studies, but not in the American study, a high MELD score was found to have poor prognostic significance. However, in the Spanish study a high MELD score was associated with mortality when the analysis only included pre-LT variables (not shown in Table 4 ); therefore, this discrepancy makes the prognostic value of the MELD score in HCV/HIV-coinfected patients uncertain. Finally, site experience was identified as a prognostic factor in the Spanish cohort. Patients transplanted at centers with less than 1 LT per year in HIV-infected patients had a 3-fold higher risk of death. This variable was not investigated in the American study, and the French study only included patients who received LT at 1 center. The prognostic significance of these factors must be re-assessed in the context of new anti-HCV DAA.
Concerning the potential effect of ART on post-transplant outcomes, some groups have suggested that survival was significantly poorer among HIV-infected transplant recipients with post-LT antiretroviral intolerance [7, 20] . A French study demonstrated that mitochondrial toxicity potentially induced by old nucleoside analogs (didanosine, stavudine) and/or ribavirin (RBV) may worsen the recurrence of HCV infection on the liver graft [20] . However, these antiretroviral drugs are no longer used. With current ART regimens, most HCV/HIV-coinfected liver transplant recipients are virologically suppressed, with a CD4 cell count remaining above 200 cell/mm 3 over time [21] . The CD4 cell count at inclusion on the waiting list was not identified as a poor prognostic factor [8, 9] .
Recommendations

Avoid combined liver and kidney transplantation (EII).
2. Avoid LT in patients with very low pre-transplant body mass index (<21 kg/m 2 ) (EII). 3. Avoid LT in centers with a low volume of LT in HIV-infected patients and no well-organized multidisciplinary team (EII). Table 3 . Patient survival after transplantation in HCV/HIV-coinfected and HCV-monoinfected liver recipients in France [8] , Spain [9] , and the USA [10] . 1. To re-assess all prognostic factors after the full introduction of effective and well-tolerated anti-HCV DAAs.
Management of HCV recurrence before the DAA era.
( J.C. Duclos-Vallée, E. Teicher)
Recurrence of HCV infection is the main problem during the post-LT period, since it has a strongly negative impact on patient and graft survival. Similarly, studies comparing HCV/HIV-coinfected and HCV-monoinfected LT recipients showed that progression of fibrosis was significantly higher in the coinfected population. In a French study, histology findings assessed 12 months after transplant showed a mean fibrosis score of 1.7 in coinfected patients compared with 1.1 in monoinfected patients (p = 0.06); at 24 months, these scores had reached 2.4 vs. 1.4, respectively (p = 0.01) [8] . Similar results were obtained in the Spanish study [9] . In the American study, graft fibrosis was not found to be more severe in the coinfected group, although this result could be due to a bias in the analysis of progression of fibrosis between the coinfected group and the control group [10, 22] . One of the main objectives in managing HCV/HIV-coinfected patients is to avoid severe recurrence of HCV infection in the liver graft and, more specifically, the occurrence of fibrosing cholestatic hepatitis (FCH), which is associated with a particularly poor prognosis in this population. The French group recently reported a 21-month mortality rate of 82% in 11 coinfected patients with FCH [23] . Interestingly, FCH seems to be related to very severe necroinflammatory activity and high viral load at the time of recurrence of acute HCV infection, thus suggesting the need for very early anti-HCV therapy in coinfected patients with high HCV viral load shortly after LT and/or moderate to severe acute HCV infection [23] .
Since early detection of severe and/or rapidly progressive recurrence of HCV infection seems to be crucial, protocol-based liver biopsies are highly recommended as soon as the recurrence is suspected, and must be repeated at least yearly. As in non-HIVinfected LT recipients, periodical transient elastography could be very helpful when assessing progression of fibrosis.
Pegylated interferon (PegIFN) and RBV may benefit non-HIVinfected recipients with HCV re-infection. A sustained virological response (SVR) in the range of 20-30% for patients with HCV genotype 1 and 40-50% for patients with HCV genotype 3 has been recorded [24] . In the first French study analyzing the efficacy of either standard IFN alfa 2b or PegIFN with different doses of RBV (400-800 mg/day) in HCV/HIV-coinfected patients, a virological response was observed in 4 of 19 (21%) treated coinfected patients. The response was sustained in 3 (16%) [8] . In the most recent French study, in which anti-HCV therapy (mean duration 7.5 months) was administered in 40 coinfected patients after a mean of 11 months after LT, an SVR was obtained in 6 (15%) patients and a null response in 27 (67.5%) [18] . These results were recently confirmed by the American and Spanish cohort studies, with an SVR of only 10% in patients with genotype 1 [25, 26] . In the Spanish study, a 59% rate of SVR was obtained in patients with genotypes 2-3 and only 7% in patients with genotype 4.
Possible explanations for the poor results of anti-HCV therapy include (1) higher rates of premature discontinuation due to intolerability, (2) higher severity of liver disease at initiation of treatment, and (3) host factors related to HIV coinfection. The only factor associated with SVR in these patients was a non-1 genotype [25] . Experience with protease inhibitor (PI)-based triple therapy is limited to case reports, and although a higher SVR can be predicted with PI-based triple therapy, poor tolerability of PegIFN and RBV continues to hamper treatment. Earlier treatment (prior to the development of advanced fibrosis or FCH) and use of growth factors to minimize treatment discontinuations due to cytopenia have the potential to improve SVR rates with PegIFN-based therapy [25] .
Recommendations
Monitor disease progression with liver biopsy or hepatic elastography at least annually to assess for progression of fibrosis (AIII). 2. Early anti-HCV therapy is indicated in patients with moderate
or severe acute hepatitis, FCH, or rapid progression of fibrosis (AII).
Challenges
1. Given the poor virological response to IFN and RBV, other combinations must be evaluated. Since the efficacy of IFN and RBV for genotype 1 has been very low (10%), control groups with this combination should not be included in future trials.
Treatment of HCV with DAAs (P. Stock, N. Terrault)
The availability of IFN-free therapy for treatment of HCV-infected patients on the waiting list and during the post-LT period has resulted in enhanced tolerability and greater success in managing HCV infection in transplant candidates and recipients. While studies on IFN-free therapy in waiting list and post-LT HCV/ HIV-coinfected patients are not available, studies in nontransplant patients suggest that HIV infection per se does not negatively affect SVR rates; therefore, the rates of SVR seen in HCV-monoinfected LT candidates and recipients are likely to be similar in coinfected patients. In a study using sofosbuvir and RBV for 12-24 weeks (depending on the HCV genotype) in HCV/HIV-coinfected patients, the SVR rates were 76% for genotype 1, 88% for genotype 2, and 67% for genotype 3. All patients were treated with tenofovir-emtricitabine combined with efavirenz and boosted with atazanavir, darunavir, raltegravir, or rilpivirine [27] . Tolerability was excellent. The combination of sofosbuvir and RBV achieved an SVR rate of 70% and was very well tolerated in a recent prospective -a multicenter study of 40 non-HIVinfected HCV-infected LT patients with recurrent HCV, most of whom with advanced fibrosis and experienced failure of treatment with PegIFN and ribavirin [28] . The SVR rate was 62% in a compassionate access study of sofosbuvir and RBV used to treat FCH and decompensated cirrhosis in patients with recurrent HCV, [29] . Thus, for the HCV/HIV-coinfected transplant recipients, treatment with sofosbuvir and RBV would be a good option. More recently, the combination of daclatasvir and sofosbuvir with/ without RBV was used to treat post-LT patients with advanced recurrent disease and was shown to achieve on-treatment responses in 9 of 9 patients and SVR4 in 5 of 5 patients [30] . Although these numbers are small, these data would suggest that sofosbuvir and daclatasvir with/without RBV is another option for treatment of recurrent HCV infection. Importantly, sofosbuvir and daclatasvir do not interact with calcineurin inhibitors or with many HAART regimens [31] . Consequently, these drugs are ideally suited for HCV/HIV-coinfected patients. In contrast, the combination of simeprevir and sofosbuvir is recommended for HCV-monoinfected transplant patients in the USA, and data from non-transplant studies showed SVR rates of P90% [32] . However, given that simeprevir interacts with PIs, efavirenz, and ciclosporin, it is less-frequently preferred for coinfected transplant patients. The main advantage of IFN-free therapy is the marked improvement in tolerability. Moreover, RBV-sparing therapy is also expected to further enhance tolerability (RBV-associated anemia is an issue in post-LT patients).
IFN-free antiviral regimens may also be used to prevent HCV infection after transplant. In a study of HCV-monoinfected waiting list patients with HCC, pre-LT therapy with sofosbuvir and RBV achieved on-treatment responses in 93%; of those with an undetectable HCV viral load for at least 4 weeks before transplant, 95% were HCV-free after transplant [33] . This strategy is likely to be expanded as drugs with demonstrated safety in decompensated cirrhosis are approved. However, it may be limited by lack of drugs with established safety in patients with advanced decompensated cirrhosis (Child-Pugh B or C) and/or renal insufficiency. The latter is a frequent complication in patients with high MELD scores, and some drugs, such as sofosbuvir, are not recommended in patients with CrCl 630 ml/min. Thus, in the near future, options for treating HCV after transplant rather than before may be more limited in coinfected patients. A multivariable analysis of the American cohort revealed a higher frequency of multisystem organ failure/sepsis in the coinfected group, likely the result of liver dysfunction related to severe HCV recurrence. The Spanish group reported that severe infections (defined as sepsis, bloodstream infections, invasive fungal infections, CMV disease, invasive viral infection, and mycobacterial disease) increased the mortality rate almost 3-fold [34] . In the American series, there were no graft losses related to HIVassociated infections or malignancies in the coinfected group. A pre-transplant history of AIDS-related opportunistic infections or neoplasms did not significantly affect post-transplant survival. Furthermore, the incidence of surgical complications (hepatic artery thrombosis, biliary complications requiring further technical intervention, wound infections, and reoperations) was similar in both coinfected and monoinfected recipients [35] , although some authors have reported a higher incidence of arterial complications [36] . A preliminary report from Spain suggests that the incidence of de novo tumors in HCV/HIV-coinfected patients is similar to that recorded in non-HIV-infected LT recipients: 4% vs. 5%, respectively [37] . Follow-up and screening for de novo tumors in HCV/HIV-coinfected patients should be similar to those in non-HIV-infected LT patients. The incidence of acute rejection was unexpectedly high in the coinfected group, and management of this complication had a very significant impact on the outcome. In the American multicenter study, the cumulative incidence of acute rejection at 3 years was 39% in the coinfected group compared with 24% in the monoinfected group (p = 0.01) [10] . A similar incidence was seen in the Spanish study [9] . More than 50% of the rejection episodes occurred within 21 days after the transplant, and most were graded as moderate to severe by a central pathologist [10] . Furthermore, treatment of acute rejection was significantly correlated with progression to severe fibrosis associated with recurrence of HCV infection, as were poorer graft and patient survival. Interactions between calcineurin inhibitors and PIs may have contributed to the higher incidence of rejection observed in HIV-infected recipients. The results from series in France and Spain suggest that raltegravir-based regimens and avoidance of PIs may reduce the high rejection rates following LT [38, 39] . Minimizing the impact of drug interactions to reduce immunosuppression may help reduce rejection rates, but the higher incidence of rejection could also be related to immune activation and dysregulation associated with HIV infection. Current studies are attempting to dissect the mechanisms responsible for the high incidence of rejection, and strategies to minimize this complication will be an important step forward in improving the results in the HCV/HIV-infected cohort.
PI-sparing antiretroviral regimens based on the integrase inhibitor raltegravir will facilitate adequate immunosuppressive coverage and hopefully lead to a decrease in the high rates of rejection observed in the initial trials. Finally, access to better tolerated and more efficacious HCV treatment regimens, before and after transplantation, is necessary to facilitate prevention and management of rejection in case of recurrent HCV disease. 2. If PIs are necessary to control HIV infection, strict and frequent monitoring of immunosuppressive drug levels is required to minimize the risk of rejection and toxicity (AII).
Challenges
1. Based on the high incidence of rejection observed in HCV/HIVcoinfected liver transplant recipients, treatment of HCV infection with IFN-based strategies after transplant can potentially exacerbate the already high incidence of rejection. Therefore, the availability of IFN-free regimens will facilitate post-transplant outcomes.
HIV-infection after liver transplantation. Antiretroviral therapy
HIV infection is very well controlled with ART after LT. Several cohort studies have shown that most patients remained virologically suppressed with good immunological control and with a low rate of opportunistic infections [8] [9] [10] . Antiretroviral drug regimens in LT recipients should follow general recommendations for ART, namely combining 2 nucleoside reverse transcriptase inhibitors (NRTI, tenofovir and emtricitabine or abacavir and lamivudine) plus a non-NRTI (efavirenz), or a ritonavir-boosted PI (atazanavir, darunavir), or an integrase inhibitor (raltegravir, elvitegravir/cobicistat, dolutegravir) [40, 41] . Abacavir must only be given if both donor and recipient are HLA-B57 * 01-negative in order to avoid a life-threatening hypersensitivity reaction [40, 41] . Tenofovir should be used with caution, and its dosage must be adjusted to the glomerular filtration rate in LT recipients with renal failure [40, 41] . The combination of elvitegravir/cobicistat/tenofovir/emtricitabine is not recommended in patients with mild or moderate renal insufficiency (estimated CrCl <70 ml/min) and is rarely used in transplant settings.
Pharmacokinetic/pharmacodynamic (PK/PD) interactions between ART, immunosuppressive drugs, and anti-HCV drugs are frequent [42] [43] [44] [45] . As ritonavir and cobicistat are strong CYP450 inhibitors that can increase many times the AUC of calcineurin inhibitors (ciclosporin and tacrolimus), Efavirenz, a modest CYP450 inducer, has been the preferred antiretroviral for many years [8] [9] [10] . However, the recent introduction of raltegravir, the first HIV integrase inhibitor, prevents these PK/PD interactions because it is not a substrate of CYP450 and does not influence the activity of this enzyme complex [38] . Therefore, the combination of 2 NRTIs plus raltegravir is currently the antiretroviral regimen of choice for HIV-infected LT recipients. Dolutegravir has a similar PK safety profile as raltegravir, although there is no experience in transplantation.
Other major PK/PD interactions have been recognized with the HCV NS3/4A PIs boceprevir and telaprevir [42, 44, 45] . These drugs had significant and non-predictable interactions with antiretrovirals, particularly non-NRTIs and HIV PIs, thus precluding many combinations. In addition, telaprevir and boceprevir also increased levels of calcineurin inhibitors by a magnitude similar to that seen with HIV ritonavir-boosted PIs. Therefore, if boceprevir or telaprevir are used, the ideal concomitant antiretroviral regimen is the combination of 2 NRTIs plus raltegravir. Simeprevir is the only second-generation DAA that interacts with specific antiretroviral and immunosuppressive drugs (see above); sofosbuvir interacts neither with antiretrovirals nor with immunosuppressive drugs. Table 5 summarizes the interactions between ART, DAA, and immunosuppressive drugs [46, 47] . Sofosbuvir and the combination of sofosbuvir/ledipasvir is not recommended in patients with estimated CrCl <30 ml/min. Therapeutic drug monitoring is indicated in all HCV/HIVinfected liver recipients. Finally, given the speed with which new antiretroviral and anti-HCV drugs are being introduced in clinical practice and the consequent report of new interactions, physicians should consult updated databases on drug interactions in HIV and HCV infection [48, 49] . HCC is a growing indication for LT in HIV-infected patients [50] [51] [52] [53] . Patients should fulfill the Milan criteria (1 HCC of 65 cm, or P3 nodules of 63 cm, with no vascular invasion or extrahepatic spread), which led to a 4-year survival of 75% in non-HIVinfected LT recipients, with recurrence rates of <15% [54] . It remains unclear whether these criteria can be expanded in HIV-infected patients. In 2011, Vibert et al. [50] reported the results of a case-control study of patients with HCC and listed for LT (21 HIV-infected patients and 65 non-HIV-infected controls). HIV-infected patients underwent LT less frequently than non-HIV-infected controls (77% vs. 90%) and had a higher waiting list dropout rate owing to tumor progression (23% vs. 10%, despite a similar initial tumor stage in both groups), lower survival from listing (81% vs. 91% at 1 year; and 55% vs. 82% at 3 years), and higher post-LT tumor recurrence (30% vs. 15%). Conversely, Italian researchers [51] analyzed data from 30 HIV-infected patients and 125 non-HIVinfected controls who underwent LT for HCC and found no significant differences in HCC recurrence (7% vs. 14%, respectively) or survival rates (77% vs. 86% at 1 year after LT and 65% vs. 70% at 3 years). In a preliminary analysis from Spain [55] , a similar incidence of HCC recurrence was observed in coinfected and monoinfected patients: 16% vs. 14%, respectively. 
